Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is set to commence this February. 

The study, to be led by Prof. Anders Fink-Jensen and Ph.D. candidate Mathias Ebbesen Jensen, will assess Filament’s natural psilocybin drug candidate for the treatment of Alcohol Use Disorder (AUD).

Filament’s co-founder and CEO Benjamin Lightburn is enthusiastic. “Psychiatric Center Copenhagen is an internationally …

Full story available on